British Society for Haematology. Listening. Learning. Leading British Society for Haematology. Listening. Learning. Leading
020 7713 0990
Annual Scientific Meeting
Login
Sign Up
Apply for Membership Website Registration
020 7713 0990
  • About Us
    • Contact Us
    • Board of Trustees
    • Committees
      • BSH Enterprises
      • Communications
      • Education
      • External Affairs
      • Finance
      • Governance
      • Guidelines
      • Programme
      • Research and Grants
    • Special Interest Groups
      • Global Haematology SIG
      • Laboratory SIG
      • Lymphoma SIG
      • Myelodysplastic Syndrome SIG
      • Obstetric Haematology SIG
      • Paediatric SIG
      • Teenage and Young Adult SIG
    • Early Careers Forum
    • Awards and Prizes
    • Volunteer with us
      • External Opportunities
    • Articles of Association, Regulation and Signed Accounts
    • Work for us
    • Strategy 2024-26: Improving lives in the haematology community
    • Website FAQs
  • Education
    • Conference and events
      • Events
      • Annual Scientific Meeting
      • Promote your haematology event
      • Event Terms and Conditions
      • Crucible Prize
      • Event FAQs
    • Lectures and Videos
      • The Limbic coverage of Annual Scientific Meeting 2024
      • Annual Scientific Meeting 2023
      • 2023 BSH ASM Birmingham - Selected Sessions
      • Previous Pitfall Lectures and Videos
      • Haematology Essentials
      • Demonstration Videos
      • Global SIG Virtual CPD talks
    • Education resources
      • Case Reports
      • Multiple Choice Questions
      • Essay Questions
      • Extended Matching Questions
      • ST3 Laboratory Induction
      • External Resources & Other Organisations
      • Haematology images
    • Students
    • Submit content
  • Grants
    • Annual Scientific Meeting Scholarships
    • ASH-BSH Abstract Achievement Award
    • Cohort Study Grant
    • Early-Stage Research Start-up Grants
    • Genomics Grant
    • Global Haematology Scholarship
    • Meeting Support
    • Student Elective Scholarships
    • Trainee Educational Bursaries
    • Travel Scholarships
    • Visiting Fellow
    • Grants - our impact
    • Grants FAQs
  • Guidelines
    • About our Guidelines
    • Proposing and writing a new BSH Guideline
    • Sounding Board
  • Membership
    • Membership Signup
    • Meet our members
    • Member updates
    • Your career and wellbeing
    • British Journal of Haematology
    • BSH-EHA Joint Membership
    • Membership FAQs
    • Event Proposal
    • Membership Survey 2020
  • News
  • Advocacy
    • The Haematology Workforce
  • Home
  • About Us
  • News

News

For information from Medicines and Healthcare products Regulatory Agency: Class 2 Medicines recall: Mercaptopurine 50mg Tablets
BSH are sharing this message from the Medicines and Healthcare products Regulatory Agency: The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 Medicines Recall of a specific batch of Mercaptopurine 50mg tablets as a precautionary measure, due to microbial contamination following a small number of complaints of discoloured tablets within the packs, identified when the packs have been opened by healthcare professionals.  Mercaptopurine is a medication used for the treatment of acute leukaemia in adults, adolescents and children. It can also be used to treat ulcerative colitis and Crohn’s disease, although use for these conditions is unlicensed.  Healthcare professionals are asked to quarantine a...
1 day ago
Related
AML drug resistance factors identified
1 day ago
Genomic scoring system for myeloma progression
1 day ago
Hope for reducing blood transfusion for children receiving stem cell transplants
1 day ago
For information from Medicines and Healthcare products Regulatory Agency: Class 2 Medicines recall: Mercaptopurine 50mg Tablets
1 day ago
For information from Medicines and Healthcare products Regulatory Agency: Class 2 Medicines recall: Mercaptopurine 50mg Tablets
BSH are sharing this message from the Medicines and Healthcare products Regulatory Agency: The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 Medicines Recall of a specific batch of Mercaptopurine 50mg tablets a...
1 day ago
Hope for reducing blood transfusion for children receiving stem cell transplants
The threshold for children receiving blood transfusion during stem cell transplants could be safely reduced, according to a UK-led study. A small pilot feasibility study, organised by NHS Blood and Transplant, was the first test of the question fo...
1 day ago
Genomic scoring system for myeloma progression
1 day ago
AML drug resistance factors identified
1 day ago
May 2025 Message from BSH President - Dr Sue Pavord
6 days ago
Technology monitors real-time platelet activity
15 days ago
1 2 3 4 5 6 7 8 9 10 11

Most popular articles

  1. Blood stem cells diversify earlier than thought
  2. Backing for new treatment for chronic graft versus host disease
  3. Mutations study offers hope for myelodysplastic syndromes patients
  4. New blood platelet tool easier and more precise
  5. New hope of eradicating aggressive form of AML
  6. CD20-directed immunotherapy resistance partially explained
  7. Risk of blood clots falls rapidly after stopping hormonal contraceptives
  8. Common beta blocker to be trialled for sickle cell cardiomyopathy
  9. Prophylactic treatment may prevent myeloma immunotherapy side effects
  10. Age affects diagnosis of von Willebrand disease
© British Society for Haematology 2025
The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 02645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. Phone: 020 7713 0990
  • Terms
  • Processing Notice
  • Sitemap